2024
Risk Score for Hepatocellular Cancer in Adults Without Viral Hepatitis or Cirrhosis
Ilagan-Ying Y, Gordon K, Tate J, Lim J, Torgersen J, Re V, Justice A, Taddei T. Risk Score for Hepatocellular Cancer in Adults Without Viral Hepatitis or Cirrhosis. JAMA Network Open 2024, 7: e2443608. PMID: 39504020, PMCID: PMC11541635, DOI: 10.1001/jamanetworkopen.2024.43608.Peer-Reviewed Original ResearchConceptsClassification of DiseasesBody mass indexRisk scoreNinth Revision and International Statistical Classification of DiseasesMass indexAlcohol useInternational Statistical Classification of DiseasesStatistical Classification of DiseasesElectronic health recordsNon-Hispanic blacksInternational Classification of DiseasesNon-Hispanic whitesClinical Modification diagnosisHepatocellular carcinoma risk scoreRisk of hepatocellular carcinomaCox proportional hazards regression modelsValidation sampleHigh-risk individualsProportional hazards regression modelsHCC risk factorsFIB-4Multivariate risk scoreHepatocellular carcinomaHazards regression modelsViral hepatitis
2023
Prevalence and characteristics of hepatitis delta virus infection in patients with hepatitis B in the United States: An analysis of the All-Payer Claims Database
Gish R, Jacobson I, Lim J, Waters-Banker C, Kaushik A, Kim C, Cyhaniuk A, Wong R. Prevalence and characteristics of hepatitis delta virus infection in patients with hepatitis B in the United States: An analysis of the All-Payer Claims Database. Hepatology 2023, 79: 1117-1128. PMID: 37976395, PMCID: PMC11020024, DOI: 10.1097/hep.0000000000000687.Peer-Reviewed Original ResearchConceptsHBV/HDV infectionLiver complicationsAll-Payer Claims DatabaseClaims databaseRisk of liver-related morbidityHepatitis delta virus infectionPrevalence of HDVDelta virus infectionProportion of patientsTime of diagnosisLiver-related morbidityUS insured populationHDV prevalenceHBV populationsHIV infectionCompensated cirrhosisDecompensated cirrhosisHBV infectionDelayed diagnosisHDV infectionHepatitis BViral hepatitisHBV/HDVPatient characteristicsSevere form
2020
AGA Institute Rapid Review and Recommendations on the Role of Pre-Procedure SARS-CoV-2 Testing and Endoscopy
Sultan S, Siddique SM, Altayar O, Caliendo AM, Davitkov P, Feuerstein JD, Francis D, Inadomi J, Lim JK, Falck-Ytter Y, Mustafa RA, Association A. AGA Institute Rapid Review and Recommendations on the Role of Pre-Procedure SARS-CoV-2 Testing and Endoscopy. Gastroenterology 2020, 159: 1935-1948.e5. PMID: 32735862, PMCID: PMC7386603, DOI: 10.1053/j.gastro.2020.07.043.Peer-Reviewed Original ResearchMeSH KeywordsAntibodies, ViralAsymptomatic InfectionsBetacoronavirusClinical Laboratory TechniquesCommunicable Disease ControlCoronavirus InfectionsCOVID-19COVID-19 TestingEndoscopyGastroenterologyHumansInfectious Disease Transmission, Patient-to-ProfessionalPandemicsPersonal Protective EquipmentPneumonia, ViralPractice Guidelines as TopicPredictive Value of TestsPreoperative CarePrevalenceRNA, ViralSARS-CoV-2Societies, MedicalUnited StatesPrevalence of Chronic Hepatitis B Virus Infection in the United States.
Lim JK, Nguyen MH, Kim WR, Gish R, Perumalswami P, Jacobson IM. Prevalence of Chronic Hepatitis B Virus Infection in the United States. The American Journal Of Gastroenterology 2020, 115: 1429-1438. PMID: 32483003, DOI: 10.14309/ajg.0000000000000651.Peer-Reviewed Original ResearchConceptsChronic hepatitis B virus infectionHepatitis B virus infectionB virus infectionWorld Health OrganizationChronic HBVVirus infectionMajor global health problemChronic HBV infectionGlobal health problemHBV prevalenceHBV infectionHBV screeningLiver cirrhosisSubstantial morbidityLiver diseaseClinical complicationsHepatocellular carcinomaHealth problemsElimination planPrevalenceDisease FoundationHealth OrganizationInfectionPeer-reviewed literatureUnited StatesAGA Institute Rapid Review of the Gastrointestinal and Liver Manifestations of COVID-19, Meta-Analysis of International Data, and Recommendations for the Consultative Management of Patients with COVID-19
Sultan S, Altayar O, Siddique SM, Davitkov P, Feuerstein JD, Lim JK, Falck-Ytter Y, El-Serag HB, . AGA Institute Rapid Review of the Gastrointestinal and Liver Manifestations of COVID-19, Meta-Analysis of International Data, and Recommendations for the Consultative Management of Patients with COVID-19. Gastroenterology 2020, 159: 320-334.e27. PMID: 32407808, PMCID: PMC7212965, DOI: 10.1053/j.gastro.2020.05.001.Peer-Reviewed Original ResearchMeSH KeywordsAntiviral AgentsBetacoronavirusClinical Laboratory TechniquesCoronavirus InfectionsCOVID-19COVID-19 TestingGastroenterologyGastrointestinal DiseasesGastrointestinal TractHumansLiverLiver DiseasesLiver Function TestsPandemicsPneumonia, ViralPractice Guidelines as TopicPrevalenceReferral and ConsultationSARS-CoV-2Societies, MedicalUnited StatesConceptsNausea/vomitingPooled prevalence estimatesAbdominal painLiver manifestationsGI symptomsLiver abnormalitiesCOVID-19Prevalence estimatesPractice statementsGI symptom questionnaireLiver enzyme abnormalitiesCertainty of evidencePrevalence of diarrheaCoronavirus disease 2019Best practice statementsSystematic literature searchStudy selection processFixed-effects modelNausea/Gastrointestinal symptomsLiver functionUnique patientsGRADE frameworkSubgroup analysisSymptom questionnaireAGA Rapid Recommendations for Gastrointestinal Procedures During the COVID-19 Pandemic
Sultan S, Lim JK, Altayar O, Davitkov P, Feuerstein JD, Siddique SM, Falck-Ytter Y, El-Serag HB, Institute A. AGA Rapid Recommendations for Gastrointestinal Procedures During the COVID-19 Pandemic. Gastroenterology 2020, 159: 739-758.e4. PMID: 32247018, PMCID: PMC7118600, DOI: 10.1053/j.gastro.2020.03.072.Peer-Reviewed Original Research
2018
Healthcare resource utilization and costs by disease severity in an insured national sample of US patients with chronic hepatitis B
Nguyen MH, Ozbay AB, Liou I, Meyer N, Gordon SC, Dusheiko G, Lim JK. Healthcare resource utilization and costs by disease severity in an insured national sample of US patients with chronic hepatitis B. Journal Of Hepatology 2018, 70: 24-32. PMID: 30287341, DOI: 10.1016/j.jhep.2018.09.021.Peer-Reviewed Original ResearchConceptsAdvanced liver diseaseCompensated liver diseaseLiver diseaseDisease severityCause inpatientLiver transplantHepatitis BHealthcare utilizationHepatocellular carcinomaHigh emergency department (ED) utilizationHighest mean annual costCause inpatient admissionsChronic hepatitis BDisease statesHealthcare resource utilizationLiver disease groupEmergency department utilizationEmergency room visitsHepatocellular carcinoma groupProgressive disease statesPharmaceutical utilizationMean annual costLiver disease statesProgressive diseaseHepatitis B.
2017
Practice Patterns in Hepatitis B Virus Screening Before Cancer Chemotherapy in a Major US Hospital Network
Kwak YE, Stein SM, Lim JK. Practice Patterns in Hepatitis B Virus Screening Before Cancer Chemotherapy in a Major US Hospital Network. Digestive Diseases And Sciences 2017, 63: 61-71. PMID: 29177849, DOI: 10.1007/s10620-017-4850-1.Peer-Reviewed Original ResearchConceptsCommunity oncology clinicsCommunity teaching hospitalHBV screening rateOncology clinicTeaching hospitalHBV infectionScreening ratesCancer chemotherapyUniversity HospitalChronic hepatitis B virus infectionHepatitis B virus infectionHepatitis B Virus ScreeningHBV reactivation riskChronic HBV infectionB virus infectionHBV core antibodyHBV surface antigenAdult cancer patientsRisk of reactivationHospital networkLarge university hospitalCore antibodyHBV exposureHBV screeningBackgroundCancer patientsAmerican Gastroenterological Association Institute Guideline on the Role of Elastography in the Evaluation of Liver Fibrosis
Lim JK, Flamm SL, Singh S, Falck-Ytter YT, Association C, Gerson L, Hirano I, Nguyen G, Rubenstein J, Smalley W, Stollman N, Sultan S, Vege S, Wani S, Weinberg D, Yang Y. American Gastroenterological Association Institute Guideline on the Role of Elastography in the Evaluation of Liver Fibrosis. Gastroenterology 2017, 152: 1536-1543. PMID: 28442119, DOI: 10.1053/j.gastro.2017.03.017.Peer-Reviewed Original ResearchMedicaid Reimbursement for Oral Direct Antiviral Agents for the Treatment of Chronic Hepatitis C
Ooka K, Connolly JJ, Lim JK. Medicaid Reimbursement for Oral Direct Antiviral Agents for the Treatment of Chronic Hepatitis C. The American Journal Of Gastroenterology 2017, 112: 828. PMID: 28374816, DOI: 10.1038/ajg.2017.87.Peer-Reviewed Original Research
2016
Optimal timing for hepatitis C therapy in US patients eligible for liver transplantation: a cost‐effectiveness analysis
Njei B, McCarty TR, Fortune BE, Lim JK. Optimal timing for hepatitis C therapy in US patients eligible for liver transplantation: a cost‐effectiveness analysis. Alimentary Pharmacology & Therapeutics 2016, 44: 1090-1101. PMID: 27640785, DOI: 10.1111/apt.13798.Peer-Reviewed Original ResearchMeSH KeywordsAntiviral AgentsBenzimidazolesCarcinoma, HepatocellularCost-Benefit AnalysisDisease ProgressionDrug Therapy, CombinationFluorenesGenotypeHepacivirusHepatitis CHumansLiver CirrhosisLiver NeoplasmsLiver TransplantationNeoplasm Recurrence, LocalQuality-Adjusted Life YearsRibavirinSofosbuvirUnited StatesConceptsHepatitis C virusLiver transplantationTime of transplantHCV recurrencePost-LTCost-effective strategyTreatment of HCVEnd-stage liver disease (MELD) scoreOptimal timingDonor LT recipientsLiver Disease scoreHCV genotype 1Hepatitis C therapyMarkov state transition modelHepatocellular carcinoma casesBase-case analysisSeparate treatment strategiesCost-effectiveness analysisAllograft failureDecompensated diseaseOngoing viraemiaPre-LTHCV treatmentLT recipientsMELD scoreDisparities in hepatitis C testing in U.S. veterans born 1945–1965
Sarkar S, Esserman DA, Skanderson M, Levin FL, Justice AC, Lim JK. Disparities in hepatitis C testing in U.S. veterans born 1945–1965. Journal Of Hepatology 2016, 65: 259-265. PMID: 27130843, PMCID: PMC4955712, DOI: 10.1016/j.jhep.2016.04.012.Peer-Reviewed Original ResearchMeSH KeywordsHepacivirusHepatitis CHepatitis C AntibodiesHumansMaleRisk FactorsUnited StatesVeteransConceptsUnited States Preventative Services Task ForceHCV testingHCV antibodiesRisk factorsHepatitis C virus testingHepatitis C virus infectionHealth systemVeterans Administration Health SystemBirth cohort testingHCV testing practicesHepatitis C testingNational screening policyPositive HCV RNAPredictors of testingC virus infectionVA health systemAdvanced liver fibrosisVeterans Administration dataCorporate Data WarehouseHCV positivityHCV RNAAdvanced fibrosisHCV testLiver fibrosisVirus infection
2015
Drug Authorization for Sofosbuvir/Ledipasvir (Harvoni) for Chronic HCV Infection in a Real-World Cohort: A New Barrier in the HCV Care Cascade
Do A, Mittal Y, Liapakis A, Cohen E, Chau H, Bertuccio C, Sapir D, Wright J, Eggers C, Drozd K, Ciarleglio M, Deng Y, Lim JK. Drug Authorization for Sofosbuvir/Ledipasvir (Harvoni) for Chronic HCV Infection in a Real-World Cohort: A New Barrier in the HCV Care Cascade. PLOS ONE 2015, 10: e0135645. PMID: 26312999, PMCID: PMC4552165, DOI: 10.1371/journal.pone.0135645.Peer-Reviewed Original ResearchConceptsSofosbuvir/ledipasvirViral loadMedicaid coverageChild-Pugh class B diseaseInitial approvalEnd-stage liver disease (MELD) scoreStage liver disease scoreChronic HCV infectionClass B diseaseDrug authorizationHCV care cascadeSOF/LEDAdvanced liver diseaseBaseline viral loadHepatitis C infectionLiver Disease scoreRetrospective chart reviewHigh viral loadSignificant predictorsHigher likelihoodMedicare/MedicaidSOF/C infectionCare cascadeHCV infectionEmerging trends in hepatocellular carcinoma incidence and mortality
Njei B, Rotman Y, Ditah I, Lim JK. Emerging trends in hepatocellular carcinoma incidence and mortality. Hepatology 2015, 61: 191-199. PMID: 25142309, PMCID: PMC4823645, DOI: 10.1002/hep.27388.Peer-Reviewed Original ResearchConceptsIB mortalityHCC incidenceHepatocellular carcinomaIncidence of HCCMultivariable Cox regression analysisOverall median survivalCox regression analysisEnd Results (SEER) dataSignificant survival improvementAge-adjusted incidenceU.S. populationHepatocellular carcinoma incidenceJoinpoint Regression ProgramIncidence-based mortalityRegression analysisSignificant increaseCurative modalityLiver transplantCurative stageMedian survivalSurvival improvementCarcinoma incidenceTumor sizeVascular invasionPrimary tumor
2009
Management and Treatment of Patients With Cirrhosis and Portal Hypertension: Recommendations From the Department of Veterans Affairs Hepatitis C Resource Center Program and the National Hepatitis C Program
Garcia-Tsao G, Lim J. Management and Treatment of Patients With Cirrhosis and Portal Hypertension: Recommendations From the Department of Veterans Affairs Hepatitis C Resource Center Program and the National Hepatitis C Program. The American Journal Of Gastroenterology 2009, 104: 1802. PMID: 19455106, DOI: 10.1038/ajg.2009.191.Peer-Reviewed Original ResearchMeSH KeywordsCause of DeathDiagnostic ImagingDisease ProgressionEvidence-Based MedicineFemaleGastrointestinal HemorrhageHepatitis C, ChronicHepatorenal SyndromeHumansHypertension, PortalImmunohistochemistryLiver CirrhosisLiver FailureLiver Function TestsMaleRandomized Controlled Trials as TopicRisk AssessmentSeverity of Illness IndexSurvival AnalysisUnited StatesUnited States Department of Veterans AffairsConceptsVariceal hemorrhageSevere complicationsHepatocellular carcinomaAcute variceal hemorrhageComplications of cirrhosisPresence of ascitesChronic liver diseaseSpontaneous bacterial peritonitisTreatment of ascitesRandomized clinical trialsTreatment of patientsStratification of patientsDifferent risk groupsQuality of lifeDecompensated patientsHepatorenal syndromeHepatitis CPortal hypertensionCirrhotic patientsProspective trialBacterial peritonitisHemodynamic alterationsLiver diseaseTreatment adherenceAscites formation